Op[us] egregiu[m] / beatissimi Bernardi amplecte[n]s [ser]mo[n]es ei[us] de t[em]p[or]e, [et] sup[er] o[mn]es fere toti[us] a[n]ni festiuitates ...

Huecos para iniciales con letras de aviso

Iacob[?] de forliuio sup[er] techni. : Antiqua Michotechni Galeni tra[n]slatio cum co[m]mento Haly Rodoan, Noua eiusdem Galeni translatio cu[m] expositione Iacobi forliuie[n]sis multotiens impressa ...

Marca tip. en A7v

Emine[n]tissimi atq[ue] s[u]btilissimi cesarei doctoris Didaci d' Segura ... repetitiones dece[m] in diuersis materiis ... : [et] proficuus ad modu[m] de bonis p[er] maritu[?] hereticu[?] constante matrimonio sup[er] lucratis tractatus ...

Pie de imp. tomado del colofón

Incipit scriptu[m] sup[er] primo sente[n]tia[rum] / editum a fratre Ioanne duns ordinis fratrum mino[rum] doctore subtilissimo ...

Marca tip. de los editores en 2i10r (Kristeller. It.B., 238)

Incipit scriptu[m] / sancti Thome de Aquino ordinis predicato[rum] sup[er] primo libro sente[n]tiaru[m] ; cu[m] textu singulis distinctionibus anteposito.

Huecos para iniciales con letras de aviso

Tabule ad diuersas huius operis magistri Guilhelmi de ockam sup[er] quattuor libros s[e]n[tent]iaru[m] a[n]notat[i]o[n]es et ad ce[n]tilogij theologici eiusdem co[n]clusiones facile reperiendas apprime conducibiles.

Pie de imp. tomado del colofón en X10r

Sexta pars biblie cu[m] glosa ordinaria [et] expositio[n]e lyre litterali [et] morali : necno[n] additio[n]ib[us] ac replicis : sup[er] Ep[istol]as ad Romanos, Corinthios, Galathas, Ephesios, Philippenses, Colossenses, Thessalonicenses, Timotheum, Titum,

Capitulares miniadas

Sermones Sancti Vincentii ordinis predicatorum de sanctis Ite[m] sup[er] or[ati]one d[omi]nica eiusde[m] VII sermones, Item eiusdem quidam alii sermones valde solennes

En el catálogo colectivo de la BNF tienen 1 vol. en tres partes con todos los sermones, éste coincidiría con la tercera

Tabula nuber diligenter correcta totius summe beati Antonini archiepiscopi florentini... ; Itez sup materias predicables de btâ virgine ; item sup auctoritates expositas in dicta summa de tota biblia...

Colofón con marca tip

Cellular mechanisms for resolving phase ambiguity in the owl's inferior colliculus

Both mammals and birds use the interaural time difference (ITD) for localization of sound in the horizontal plane. They may localize either real or phantom sound sources, when the signal consists of a narrow frequency band. This ambiguity does not occur with broadband signals. A plot of impulse rates or amplitude of excitatory postsynaptic potentials against ITDs (ITD curve) consists of peaks and troughs. In the external nucleus (ICX) of the owl's inferior colliculus, ITD curves show multiple peaks when the signal is narrow-band, such as tones. Of these peaks, one occurs at ITDi, which is independent of frequency, and others at ITDi ± T, where T is the tonal period. The ITD curve of the same neuron shows a large peak (main peak) at ITDi and no or small peaks (side peaks) at ITDi ± T, when the signal is broadband. ITD curves for postsynaptic potentials indicate that ICX neurons integrate the results of binaural cross-correlation in different frequency bands. However, the difference between the main and side peaks is small. ICX neurons further enhance this difference in the process of converting membrane potentials to impulse rates. Inhibition also appears to augment the difference between the main and side peaks.

GABAergic feedforward projections from the inferior colliculus to the medial geniculate body.

A novel and robust projection from gamma-aminobutyric acid-containing (GABAergic) inferior colliculus neurons to the media] geniculate body (MGB) was discovered in the cat using axoplasmic transport methods combined with immunocytochemistry. This input travels with the classical inferior colliculus projection to the MGB, and it is a direct ascending GABAergic pathway to the sensory thalamus that may be inhibitory. This bilateral projection constitutes 10-30% of the neurons in the auditory tectothalamic system. Studies by others have shown that comparable input to the corresponding thalamic visual or somesthetic nuclei is absent. This suggests that monosynaptic inhibition or disinhibition is a prominent feature in the MGB and that differences in neural circuitry distinguish it from its thalamic visual and somesthetic counterparts.

Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108

PURPOSE: Malignant ascites is debilitating for patients with advanced cancer. As shown previously, tumour cell production of vascular endothelial growth factor might be a major cause of the formation of malignant ascites. Intraperitoneal bevacizumab could therefore be an option for symptom control in refractory ascites. PATIENTS AND METHODS: Patients with advanced gastrointestinal cancer and malignant ascites who had undergone paracentesis at least twice within the past 4 weeks were randomly assigned in a 2:1 ratio to intraperitoneal bevacizumab (400 mg absolute) or placebo after paracentesis. During the 8-week treatment period, a minimum interval of 14 d was kept between the applications of the study drug. Primary end-point was paracentesis-free survival (ParFS). RESULTS: Fifty-three patients (median age 63 years) were randomised. Forty-nine patients received at least one study drug application and qualified for the main analysis. The proportion of patients with at least one common toxicity criteria grade III-V event was similar with 20/33 (61%) on bevacizumab and 11/16 (69%) on placebo. Median ParFS was 14 d (95% confidence interval [CI]: 11-17) in the bevacizumab arm and 10.5 d (95% CI: 7-21) on placebo (hazard ratio 0.74, 95% CI: 0.40-1.37; P = 0.16). The longest paracentesis-free period was 19 d on bevacizumab (range 6-66 d) and 17.5 d in the placebo arm (range 4-42) (P = 0.85). Median overall survival was 64 d (95% CI: 45-103) on bevacizumab compared to 31.5 d (95% CI: 20-117) on placebo (P = 0.31). CONCLUSION: Intraperitoneal bevacizumab was well tolerated. Overall, treatment did not result in a significantly better symptom control of malignant ascites. However, patients defined by specific immune characteristics may benefit.